Stephanie S Faubion1,2, Ekta Kapoor1,2,3, Ann M Moyer4, Howard N Hodis5, Virginia M Miller6. 1. Center for Women's Health, Mayo Clinic, Rochester, MN. 2. Division of General Internal Medicine, Mayo Clinic, Rochester, MN. 3. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN. 4. Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN. 5. Atherosclerosis Research Unit, Departments of Medicine and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. 6. Departments of Surgery and Physiology & Biomedical Engineering, Women's Health Research Center, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: Statins are a class of drugs that competitively bind to the active site of HMG-CoA reductase enzyme, thereby inhibiting the initial steps in cholesterol synthesis. Originally approved for use in lowering serum cholesterol, a risk factor for developing atherosclerosis and coronary heart disease, statins have subsequently been noted to have myriad extrahepatic effects, including potential effects on cognition, diabetes, breast cancer, bone, and muscle. This narrative review assesses the current state of the science regarding the risks and benefits of statin therapy in women to identify areas where additional research is needed. METHODS: Basic and clinical studies were identified by searching PubMed with particular attention to inclusion of female animals, women, randomized controlled trials, and sex-specific analyses. RESULTS: Statin therapy is generally recommended to reduce the risk of cardiovascular disease. None of the current clinical guidelines, however, offer sex-specific recommendations for women due to lack of understanding of sex differences and underlying mechanisms of disease processes. In addition, conclusions regarding efficacy of treatments do not consider lipid solubility for the drug, dosing, duration of treatment, interactions with estrogen, or comorbidities. Pleiotropic effects of statins are often derived from secondary analysis of studies with cardiovascular events as primary outcomes. CONCLUSIONS: Many of the trials that have established the efficacy and safety of statins were conducted predominantly or entirely in men, with results extrapolated to women. Additional research is needed to guide clinical recommendations specific to women. : Video Summary:http://links.lww.com/MENO/A462.
OBJECTIVE: Statins are a class of drugs that competitively bind to the active site of HMG-CoA reductase enzyme, thereby inhibiting the initial steps in cholesterol synthesis. Originally approved for use in lowering serum cholesterol, a risk factor for developing atherosclerosis and coronary heart disease, statins have subsequently been noted to have myriad extrahepatic effects, including potential effects on cognition, diabetes, breast cancer, bone, and muscle. This narrative review assesses the current state of the science regarding the risks and benefits of statin therapy in women to identify areas where additional research is needed. METHODS: Basic and clinical studies were identified by searching PubMed with particular attention to inclusion of female animals, women, randomized controlled trials, and sex-specific analyses. RESULTS: Statin therapy is generally recommended to reduce the risk of cardiovascular disease. None of the current clinical guidelines, however, offer sex-specific recommendations for women due to lack of understanding of sex differences and underlying mechanisms of disease processes. In addition, conclusions regarding efficacy of treatments do not consider lipid solubility for the drug, dosing, duration of treatment, interactions with estrogen, or comorbidities. Pleiotropic effects of statins are often derived from secondary analysis of studies with cardiovascular events as primary outcomes. CONCLUSIONS: Many of the trials that have established the efficacy and safety of statins were conducted predominantly or entirely in men, with results extrapolated to women. Additional research is needed to guide clinical recommendations specific to women. : Video Summary:http://links.lww.com/MENO/A462.
Authors: Richard E Scranton; Melissa Young; Elizabeth Lawler; Daniel Solomon; David Gagnon; J Michael Gaziano Journal: Arch Intern Med Date: 2005-09-26
Authors: Leslee J Shaw; C Noel Bairey Merz; Carl J Pepine; Steven E Reis; Vera Bittner; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Sunil Mankad; Barry L Sharaf; William J Rogers; Timothy R Wessel; Christopher B Arant; Gerald M Pohost; Amir Lerman; Arshed A Quyyumi; George Sopko Journal: J Am Coll Cardiol Date: 2006-02-07 Impact factor: 24.094
Authors: L Smiderle; M Fiegenbaum; M H Hutz; C R Van Der Sand; L C Van Der Sand; M E W Ferreira; R C Pires; S Almeida Journal: Pharmacogenomics J Date: 2015-08-25 Impact factor: 3.550
Authors: Eunjung Lee; Fredrick Schumacher; Juan Pablo Lewinger; Susan L Neuhausen; Hoda Anton-Culver; Pamela L Horn-Ross; Katherine D Henderson; Argyrios Ziogas; David Van Den Berg; Leslie Bernstein; Giske Ursin Journal: Breast Cancer Res Date: 2011-04-01 Impact factor: 6.466
Authors: Jonathan R Emberson; Patricia M Kearney; Lisa Blackwell; Connie Newman; Christina Reith; Neeraj Bhala; Lisa Holland; Richard Peto; Anthony Keech; Rory Collins; John Simes; Colin Baigent Journal: PLoS One Date: 2012-01-19 Impact factor: 3.240
Authors: Saraschandra Vallabhajosyula; Shiva P Ponamgi; Sanskriti Shrivastava; Pranathi R Sundaragiri; Virginia M Miller Journal: FASEB J Date: 2020-07 Impact factor: 5.191
Authors: So Young Kim; Dae Myoung Yoo; Chanyang Min; Ji Hee Kim; Mi Jung Kwon; Joo-Hee Kim; Hyo Geun Choi Journal: Int J Environ Res Public Health Date: 2021-11-12 Impact factor: 3.390
Authors: Gonçalo S Clemente; Inês F Antunes; Jürgen W A Sijbesma; Aren van Waarde; Adriaan A Lammertsma; Alexander Dömling; Philip H Elsinga Journal: Mol Pharm Date: 2021-08-05 Impact factor: 4.939